Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2023
The White House said Friday it was "dangerous and unacceptable" for elected officials to target women's access to federally-approved abortion pills.
Read Full NewsPatients in the phase 3 LIBREXIA ACS trial showed no reduction in cardiovascular events after acute coronary syndrome.
Statin use for primary cardiovascular prevention in adults aged 70 years or older is supported by data from STAREE, although treatment did not prolong disability-free survival.
Despite a major reduction in transthyretin amyloid deposits, eplontersen, a drug that reduces TTR production, did not reduce events associated with TTR amyloidosis in a phase 3 trial.
1.
EU Flags Shortage Of Schizophrenia Drug Injections Due to Manufacturing Issues
2.
Brain cancer: a Q&A session.
3.
Women are more susceptible to the stress caused by inflation.
4.
Use of social media during pregnancy may increase depression.
5.
A new theranostic drug targets different cancer types.
1.
Unlocking the Mysteries of the Axillary Vein: Exploring its Role in Human Anatomy
2.
How HLH is Revolutionizing Healthcare
3.
Unraveling the Mysteries of Burkitt Lymphoma: A New Hope for Treatment
4.
Landmark Medical Oncology Trials Redefining Early Breast Cancer Management
5.
Rehabilitation Through Prehabilitation Before Complex Cancer Surgery
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in MRD Negativity
2.
Dissecting Molecular differences between EGFR Exon 19 deletion and Exon 21 L858R Mutations
3.
Should We Use DARA Up Front As First-Line Therapy in MM? - Part II
4.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part I
5.
From Relapse to Remission Mapping the Treatment Journey in Adult R R B Cell ALL The Critical Goal of MRD
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge